CENTENE CORP (CNC)
Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment offers the temporary assistance for needy families; medicaid expansion; aged, blind, or disabled; and children's health insurance programs, as well as long-term services and supports; foster care; and medicare-medicaid plans. This segment also provides healthcare products and services. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual and commercial group. The Other segment operates clinical healthcare and pharmacies, as well as offers vision and dental, behavioral health, and centralized services. It provides services through primary and specialty care physicians, hospitals, behavioral health practitioners, and ancillary providers. The company was founded in 1984 and is headquartered in Saint Louis, Missouri.
Open CENTENE CORP in the interactive graph- Ticker
- CNC
- SEC CIK
- 0001071739
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Periods
- FY2025 Q1, FY2025 Q4, FY2026, FY2026 Q1, FY2026 Q3, FY2027
- Headquarters
- Saint Louis, MO
- Employees
- 61,100
Key figures
- Revenue 44.66B USD
- NetIncome 1.54B USD
- DilutedEPS 3.37 USD/share
Reported figures
- BasicSharesOutstanding 492,069,000.00 shares
- BasicSharesOutstanding 496,214,000.00 shares
- CapitalExpenditure 135.00M USD
- CapitalExpenditure 200.00M USD
- CashAndEquivalents 17.89B USD
- CashAndEquivalents 21.26B USD
- DilutedEPS 2.63 USD/share
- DilutedEPS 2.90 USD/share
- DilutedEPS 3.11 USD/share
- DilutedEPS 3.37 USD/share
- FreeCashFlow 3.40B USD
- GrossProfit 10.94B USD
- InterestExpense 164.00M USD
- InterestExpense 170.00M USD
- NetIncome 1.31B USD
- NetIncome 1.45B USD
- NetIncome 1.54B USD
- NetIncome 1.67B USD
- OperatingCashFlow 1.51B USD
- OperatingCashFlow 4.37B USD
- OperatingIncome 1.53B USD
- OperatingIncome 1.86B USD
- OtherMetric 20.63B USD
- OtherMetric 24.7 percent
- OtherMetric 26.5 percent
- OtherMetric 26.7 percent
- OtherMetric 382.00M USD
- OtherMetric 407.00M USD
- OtherMetric 41.77B USD
- OtherMetric 48 days
- OtherMetric 7.6 percent
- OtherMetric 7.9 percent
- OtherMetric 75 percent
- OtherMetric 75.3 percent
- OtherMetric 84.9 percent
- OtherMetric 86.3 percent
- OtherMetric 87.3 percent
- OtherMetric 87.5 percent
- OtherMetric 93.1 percent
- OtherMetric 93.6 percent
- and 14 more in the interactive graph
Guidance
- DilutedEPS guidance 2.37 USD/share
- DilutedEPS guidance 3.40 USD/share
- OtherMetric guidance 1.45B USD
- OtherMetric guidance 26–27 percent
- OtherMetric guidance 27–28 percent
- OtherMetric guidance 7–7.6 percent
- OtherMetric guidance 90.9–91.7 percent
- Revenue guidance 171.00B–175.00B USD
- Revenue guidance 187.50B–191.50B USD
- SharesOutstanding guidance 495,600,000.00–498,600,000.00 shares
Drivers
- Cash flow provided by operations primarily driven by net earnings, the partial sale of the
- Commercial HBR slightly above expectations, primarily reflecting higher acuity among Marke
- Consolidated HBR decrease driven by an increase to the premium deficiency reserve in 2025
- HBR decrease partially offset by the decline in Marketplace membership and the correspondi
- Medicaid HBR decreased by 50 basis points primarily driven by rate and revenue increases,
- Medicare segment HBR of 84.9%, from outperformance in both Medicare Advantage and PDP
- Premium and service revenues increase primarily driven by premium yield and membership gro
- SG&A expense ratio decrease driven by growth in the PDP business, which operates at a mean
- SG&A expense ratio decrease primarily driven by strong cost management, leveraging of expe
Corporate events
- Repurchased $1.0 billion of the Company's par value senior notes due 2027 in March 2026
- Sold a participating interest of $1.0 billion of 2025 plan year stand-alone Part D risk-sh